A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5

Cancer Letters

Volumn 380, Issue 2, 2016, Pages 393-402

  Wu, Jing ^a,b,c   Ding, Ye ^d   Chen, Chuan Huizhi ^a   Zhou, Zhongmei ^a   Ding, Chunyong ^d   Chen, Haiying ^d   Zhou, Jia ^d   Chen, Ceshi ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Apoptosis; Death receptor 5 (DR5); Oridonin analog; Therapy; Triple negative breast cancer

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CYCLIN D1; CYD 6 28; DEATH RECEPTOR 5; DOXORUBICIN; FLICE INHIBITORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORIDONIN; PROTEIN KINASE B; PROTEIN P21; STAT3 PROTEIN; TERPENOID; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN; CYD-6-28; KAURANE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN, HUMAN; TNFRSF10B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER CELL LINE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; AGONISTS; ANIMAL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TIME FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES, KAURANE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978640737     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.06.024     Document Type: Article

References (51)

1. [1] Fan, L., Strasser-Weippl, K., Li, J.-J., St Louis, J., Finkelstein, D.M., Yu, K.-D., et al. Breast cancer in China. Lancet Oncol 15 (2014), e279–e289.
2. [2] Chacon, R.D., Costanzo, M.V., Triple-negative breast cancer. Breast Cancer Res, 12(Suppl. 2), 2010, S3.
3. [3] Foulkes, W.D., Smith, I.E., Reis-Filho, J.S., Triple-negative breast cancer. N. Engl. J. Med 363 (2010), 1938–1948.
4. [4] Hudis, C.A., Gianni, L., Triple-negative breast cancer: an unmet medical need. Oncologist 16:Suppl. 1 (2011), 1–11.
5. [5] Sun, H.D., Huang, S.X., Han, Q.B., Diterpenoids from Isodon species and their biological activities. Nat. Prod. Rep 23 (2006), 673–698.
6. [6] The Pharmacopoecia of People's Republic of China, 1977, People's Health Press, Beijing, 186.
7. [7] Fujita, E., Nagao, Y., Node, M., Kaneko, K., Nakazawa, S., Kuroda, H., Antitumor activity of the Isodon diterpenoids: structural requirements for the activity. Experientia 32 (1976), 203–206.
8. [8] Fujita, E., Nagao, Y., Kaneko, K., Nakazawa, S., Kuroda, H., The antitumor and antibacterial activity of the Isodon diterpenoids. Chem. Pharm. Bull 24 (1976), 2118–2127.
9. [9] Ikezoe, T., Chen, S.S., Tong, X.J., Heber, D., Taguchi, H., Koeffler, H.P., Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int. J. Oncol 23 (2003), 1187–1193.
10. [10] Chen, S., Gao, J., Halicka, H.D., Huang, X., Traganos, F., Darzynkiewicz, Z., The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int. J. Oncol 26 (2005), 579–588.
11. [11] Qing xia Fan, Li, X.Y., Wang, R.L., Treatment by Rabdosia rubescens for esophageal cancer. Chin. J. Surg. Integr. Traditional Western Med 06 (1997), 23–24.
12. [12] Qing xia Fan, Wang, R., Wang, R.L., Clinical efficacy of treatment by Rabdosia rubescens alone or in combination chemotherapy for esophageal cancer. World Chin. J. Digestol 15 (2007), 2534–2537.
13. [13] Li, C.Y., Wang, E.Q., Cheng, Y., Bao, J.K., Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int. J. Biochem. Cell Biol 43 (2011), 701–704.
14. [14] Liu, Z., Ouyang, L., Peng, H., Zhang, W.Z., Oridonin: targeting programmed cell death pathways as an anti-tumour agent. Cell Prolif 45 (2012), 499–507.
15. [15] Zhang, X., Chen, L.X., Ouyang, L., Cheng, Y., Liu, B., Plant natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents. Cell Prolif 45 (2012), 466–476.
16. [16] Xu, W., Sun, J., Zhang, T.T., Ma, B., Cui, S.M., Chen, D.W., et al. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol. Sin 27 (2006), 1642–1646.
17. [17] Xu, W., Sun, J., Zhang, T., Ma, B., Chen, D., He, Z., Determination of equilibrium solubility of oridonin and its apparent oil/water partition coefficient by HPLC. J. Shenyang Pharm. Univ, 2007, 220–222.
18. [18] Xu, J., Yang, J., Ran, Q., Wang, L., Liu, J., Wang, Z., et al. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg. Med. Chem. Lett 18 (2008), 4741–4744.
19. [19] Li, D., Wang, L., Cai, H., Zhang, Y., Xu, J., Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents. Molecules 17 (2012), 7556–7568.
20. [20] Wang, L., Li, D., Xu, S., Cai, H., Yao, H., Zhang, Y., et al. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents. Eur. J. Med. Chem 52 (2012), 242–250.
21. [21] Li, D., Xu, S., Cai, H., Pei, L., Zhang, H., Wang, L., et al. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: synthesis and their antitumor biological evaluation. Eur. J. Med. Chem 64 (2013), 215–221.
22. [22] Shen, J., Zhang, D., Zhao, Z., Jia, L., Zheng, D., Liu, G., et al. Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates. Int. J. Pharm 456 (2013), 80–86.
23. [23] Xu, S., Li, D., Pei, L., Yao, H., Wang, C., Cai, H., et al. Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives. Bioorg. Med. Chem. Lett 24 (2014), 2811–2814.
24. [24] Ding, C., Zhang, Y., Chen, H., Yang, Z., Wild, C., Ye, N., et al. Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J. Med. Chem 56 (2013), 8814–8825.
25. [25] Ding, C., Zhang, Y., Chen, H., Yang, Z., Wild, C., Chu, L., et al. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J. Med. Chem 56 (2013), 5048–5058.
26. [26] Liu, G., Su, L., Hao, X., Zhong, N., Zhong, D., Singhal, S., et al. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J. Cell. Mol. Med 16 (2012), 1618–1628.
27. [27] Green, D.R., Apoptotic pathways: paper wraps stone blunts scissors. Cell 102 (2000), 1–4.
28. [28] Liu, Z., Ding, Y., Ye, N., Wild, C., Chen, H., Zhou, J., Direct activation of bax protein for cancer therapy. Med. Res. Rev 36 (2016), 313–341.
29. [29] Cui, Q., Yu, J.H., Wu, J.N., Tashiro, S., Onodera, S., Minami, M., et al. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol. Sin 28 (2007), 1057–1066.
30. [30] Sun, K.W., Ma, Y.Y., Guan, T.P., Xia, Y.J., Shao, C.M., Chen, L.G., et al. Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J. Gastroenterol 18 (2012), 7166–7174.
31. [31] Zhu, M., Hong, D., Bao, Y., Wang, C., Pan, W., Oridonin induces the apoptosis of metastatic hepatocellular carcinoma cells via a mitochondrial pathway. Oncol. Lett 6 (2013), 1502–1506.
32. [32] Shi, Q.F., Liu, Y., Qi, M., Tashiro, S., Onodera, S., Ikejima, T., Interruption of hepatocyte growth factor signaling augmented oridonin-induced death in human non-small cell lung cancer a549 cells via c-met-nuclear factor-κB-cyclooxygenase-2 and c-met-bcl-2-caspase-3 pathways. Biol. Pharm. Bull 35 (2012), 1150–1158.
33. [33] Shu, Y., Bao, R., Wu, X., Weng, H., Ding, Q., Cao, Y., et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer 14 (2014), 1–13.
34. [34] Kang, N., Zhang, J.H., Qiu, F., Tashiro, S., Onodera, S., Ikejima, T., Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett 294 (2010), 147–158.
35. [35] Safa, A.R., Pollok, K.E., Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel) 3 (2011), 1639–1671.
36. [36] Grant, S., Harada, H., Apoptosis regulators. Rev. Clin. Exp. Hematol 7 (2003), 117–138.
37. [37] Zhang, L., Fang, B., Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12 (2005), 228–237.
38. [38] Elrod, H.A., Sun, S.-Y., Modulation of death receptors by cancer therapeutic agents. Cancer Biol. Ther 7 (2014), 163–173.
39. [39] Hetz, C., The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol 13 (2012), 89–102.
40. [40] Sano, R., Reed, J.C., ER stress-induced cell death mechanisms. Biochim. Biophys. Acta 1833 (2013), 3460–3470.
41. [41] Schonthal, A.H., Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica (Cairo), 2012, 2012, 857516.
42. [42] Yamaguchi, H., Wang, H.G., CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J. Biol. Chem 279 (2004), 45495–45502.
43. [43] Cheng, Y., Qiu, F., Ye, Y.C., Tashiro, S., Onodera, S., Ikejima, T., Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch. Biochem. Biophys 490 (2009), 70–75.
44. [44] Zhang, J.H., Kang, N., Qiu, F., Chen, S., Tashiro, S., Onodera, S., et al. Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J. Nat. Prod 73 (2010), 1058–1063.
45. [45] Li, X., Li, X., Wang, J., Ye, Z., Li, J.C., Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int. J. Biol. Sci 8 (2012), 901–912.
46. [46] Gao, F.H., Hu, X.H., Li, W., Liu, H., Zhang, Y.J., Guo, Z.Y., et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer, 10, 2010, 610.
47. [47] Abbas, T., Dutta, A., p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9 (2009), 400–414.
48. [48] Steelman, L.S., McCubrey, J.A., Abrams, S.L., Lee, J.T., Chang, F., Bertrand, F.E., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul 46 (2006), 249–279.
49. [49] Guo, Y., Shan, Q., Gong, Y., Lin, J., Yang, X., Zhou, R., Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol. Ther 13 (2012), 1244–1254.
50. [50] Yang, Y.B., Hu, H.Z., Xu, X.D., Shen, H.W., Shu, Y.M., Ren, Z., et al. Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol. Sin 28 (2007), 1819–1826.
51. [51] Shen, J.N., Jin, S., Wang, J., Huang, G., Zhou, J.G., Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol. Ther 6 (2007), 261–268.